Metabolic medicine is witnessing transformative advances. Response Pharmaceuticals’ phase II trial of RDX-002 demonstrated sustained weight loss and blood lipid reductions post-GLP-1 receptor agonist treatment, addressing weight regain challenges. At BIO 2025, experts highlighted the next generation of weight loss drugs targeting muscle health alongside fat reduction, enhancing durability and tolerability. Additionally, a gene score predicting obesity risk from early childhood offers potential for preemptive interventions. Novel therapeutics and precision medicine approaches promise better management of obesity-associated health burdens.